Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Wehless: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Wehless - General Information

Wehless is a weight loss medication. Wehless is chemically related to amphetamines and is a Schedule III drug under the Convention on Psychotropic Substances. In the United States, phendimetrazine is a Schedule III controlled substance under the Uniform Controlled Substances Act of 1970.

 

Pharmacology of Wehless

Wehless is a phenylalkylamine sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance has been demonstrated with all drugs of this class in which these phenomena have been looked for. Drugs of this class used in obesity are commonly known as ''anorectics or anorexigenics." It has not been established, however, that the action of such drugs in treating obesity is primarily one of appetite suppression. Other central nervous system actions or metabolic effects, may be involved.

 

Wehless for patients

 

Wehless Interactions

 

Wehless Contraindications

Known hypersensitivity or idiosyncratic reactions to sympathomimetics. Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate and severe hypertension, hyperthyroidism, glaucoma.

Highly nervous or agitated patients. Patients with a history of drug abuse. Patients taking other CNS stimulants, including monamine oxidase inhibitors.

 

Additional information about Wehless

Wehless Indication: Used in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. Mechanism Of Action: Not Available Drug Interactions: Not Available Food Interactions: Not Available Generic Name: Phendimetrazine Synonyms: (+)-3,4-Dimethyl-2-phenylmorpholine; (+)-phendimetrazine; (2S,3S)-3,4-Dimethyl-2-phenylmorpholine; 3,4-Dimethyl-2-phenylmorpholine; 3-Phenyl-2-methylmorpholine; d-2-Phenyl-3,4-dimethylmorpholine Drug Category: Anorexigenic Agents Drug Type: Small Molecule; Illicit; Approved Other Brand Names containing Phendimetrazine: Adphen; Antapentan; Bacarate; Bontril; Dyrexan; Hyrex; Mephenmetrazine; Sedafamen; Wehless; X-trozine; Prelu-2; Absorption: Peak plasma levels occur within 1 to 3 hours. Absorption is usually complete by 4 to 6 hours. Toxicity (Overdose): Acute overdosage of phendimetrazine may manifest itself by the following signs and symptoms: unusual restlessness, confusion, belligerance, hallucinations, and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension, or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Poisoning may result in convulsions, coma and death. Protein Binding: Not Available Biotransformation: Approximately 30% of a given dose of phendimetrazine is metabolized into phenmetrazine, which may account for part of its anorectic effect, and probably also influences abuse potential; individuals who metabolise a greater proportion of phendimetrazine into phenmetrazine are more likely to develop problems with dependence and addiction Half Life: 19-24 hours Dosage Forms of Wehless: Tablet Oral Chemical IUPAC Name: 3,4-dimethyl-2-phenylmorpholine Chemical Formula: C12H17NO Phendimetrazine on Wikipedia: https://en.wikipedia.org/wiki/Phendimetrazine Organisms Affected: Humans and other mammals